We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preliminary Results from a Phase IV Surveillance Study of Medical Cannabis Use in Australian Patients With Advanced Cancer Receiving Palliative Care.
- Authors
Gurgenci, Taylan; Hardy, Janet; Good, Christopher; Good, Phillip
- Abstract
Introduction: Our research group is conducting three large randomized placebo-controlled trials of medicinal cannabis for cancer symptoms. All participants are invited to take part in a posttrial surveillance study. Methods: Participants were given the manufacturers dosing instructions and liberty to titrate to effect. Data were collected on symptoms (Edmonton Symptom Assessment Scale [ESAS] score), perceived benefits, adverse effects, satisfaction with the product, and dose/frequency. Results: Twenty-six percent of eligible participants consented to take part in the surveillance study. Most participants changed their self-titrated dose at least once. Pain, sleep, and mood were the most frequently cited symptoms which improved. Fatigue, nausea, and cognitive impairment were the most frequently mentioned adverse effects. Conclusion: Participants felt confident making changes to their medicinal cannabis dose within the limits suggested by the manufacturer of each product. A number of benefits and adverse effects were ascribed to the product. Benefits were similar to those described in previous studies.
- Subjects
AUSTRALIA; MEDICAL marijuana; PALLIATIVE treatment; RESEARCH funding; MILD cognitive impairment; FATIGUE (Physiology); DESCRIPTIVE statistics; LONGITUDINAL method; PAIN; SLEEP; TUMORS; CANCER patient psychology; TUMOR classification; PATIENT satisfaction; NAUSEA; THERAPEUTICS
- Publication
Journal of Palliative Medicine, 2024, Vol 27, Issue 5, p663
- ISSN
1096-6218
- Publication type
Article
- DOI
10.1089/jpm.2023.0358